<DOC>
	<DOCNO>NCT01596114</DOCNO>
	<brief_summary>The EURO-SKI multicenter open label , uncontrolled trial estimate persistence molecular remission Chronic Myeloid Leukemia ( CML ) patient stop Tyrosine Kinase Inhibitor ( TKI ) . Main goal assessment duration major molecular response ( MMR ) well stop TKI therapy . Secondary goal include : - Identification clinical biological factor affect persistence complete molecular remission stop TKI ( e.g . level Complete molecular remission ( CMR ) , risk score , duration TKI treatment , type TKI pretreatment ) - Evaluation quality life ( QoL ) patient stop TKI - Evaluation medico-economic impact stop TKI - Estimating number patient CMR eligible stop TKI therapy set screen log - Time recovery CMR There randomise comparison . Based experience STIM trial ( Mahon et al. , Lancet Onc 2010 ) expect overall six-month molecular-relapse-free survival probability least 40 % . An interim analysis perform pilot phase 200 patient observe least six month . Formally , plan test null hypothesis H0 : Six-month molecular relapse-free survival probability P â‰¤ 40 % alternative hypothesis H1 : Six-month molecular-relapse-free survival probability P &gt; 40 % . Eligible adult CML patient chronic phase TKI treatment CMR least one year ( &gt; 4 log reduction BCR-ABL transcript IS , TKI treatment least 3 year , confirm PCR within standardized CMR laboratory ) . Clinical biological monitoring perform 3 year : Associated scientific project perform . Recruitment period : 2 year ; follow : 3 year . Planned patient recruitment main phase : n=500</brief_summary>
	<brief_title>European Stop Tyrosine Kinase Inhibitor Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Tin Fluorides</mesh_term>
	<criteria>CML CP treatment TKI first line second line toxicity first line TKI TKI combination Duration TKI treatment enrolment least 3 year At least complete molecular remission MR4 Before inclusion confirmation CMR4 EUTOSCMR laboratory Baseline data documentation treatment study entry available Both sex fertile woman use effective contraceptive Health insurance coverage 18 year old Under 18 year old Hospitalized patient without ability give inform consent Adults law protection without ability consent Previous plan allogeneic stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>TKI</keyword>
	<keyword>CML</keyword>
	<keyword>Stopping</keyword>
	<keyword>chronic phase</keyword>
	<keyword>remission</keyword>
</DOC>